Paul Mann, MD
Ophthalmology · Humble, TXNPI 1366447559
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Alcon at 34.4% of the total. Reporting peaked in 2022 at $19,869 and has fallen 87.2% since, to $2,548 in 2025. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 349 payments — averaging $107.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$13K
- Johnson & Johnson Vision Care, Inc.$13K
- Johnson & Johnson Surgical Vision, Inc.$4K
- AbbVie$3K
- Sun Pharmaceutical Industries Inc.$926
- Oyster Point Pharma, Inc.$668
- plus $4K from 25 others
Across 2 payments — averaging $558.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$1K
What the payments were for
- Consulting fees$2,7507%
- Speaking & faculty fees$20,00053%
- Food & beverage$14,65239%
- Education$2401%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 104 | $12,960 |
| Johnson & Johnson Vision Care, Inc. | 3 | $12,607 |
| Johnson & Johnson Surgical Vision, Inc. | 20 | $3,794 |
| AbbVie(2 entities) | 93 | $2,690 |
| Sun Pharmaceutical Industries Inc. | 25 | $926 |
| Oyster Point Pharma, Inc. | 15 | $668 |
| Novartis | 24 | $657 |
| Carl Zeiss Meditec USA, Inc. | 6 | $613 |
| Carl Zeiss Meditec, Inc. | 3 | $312 |
| Amgen | 3 | $298 |
| Tarsus Pharmaceuticals, Inc. | 4 | $277 |
| Sight Sciences, Inc. | 5 | $223 |
| Biotissue Holdings Inc. | 8 | $210 |
| Dompe US, Inc. | 3 | $185 |
| NEW World Medical,inc. | 1 | $165 |
| Carl Zeiss Meditec Cataract Technology Inc. | 1 | $144 |
| Bausch & Lomb Americas Inc. | 6 | $139 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $124 |
| Glaukos Corporation | 2 | $120 |
| Rxsight Inc | 1 | $111 |
| Beaver-visitec International, Inc. | 1 | $90 |
| Harrow Eye, LLC | 2 | $64 |
| Aerie Pharmaceuticals, Inc. | 2 | $47 |
| Eyevance Pharmaceuticals LLC | 2 | $36 |
| Astellas Pharma US Inc | 1 | $35 |
| Lensar, Inc. | 1 | $34 |
| Quidel Corporation | 2 | $32 |
| Kala Pharmaceuticals, Inc. | 2 | $27 |
| Mallinckrodt Enterprises LLC | 1 | $22 |
| Thea Pharma Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Acuvue$12,500
- DAILIES TOTAL1$7,500
- AIR OPTIX$7,500
- Precision 1$7,500
- Tecnis IOL$5,500
- Air Optix plus HydraGlyde$5,000
- Dailies Aqua Comfort Plus$5,000
- Tecnis Simplicity$2,750
- Wavelight Refractive Suite$1,070
- ARTEVO 800$508
- CEQUA$489
- TYRVAYA$425
- Wavelight$397
- VUITY$392
- DURYSTA$351
- Centurion$299
- TEPEZZA$267
- WaveLight EX500 Excimer Laser$257
- Clareon$254
- RESTASIS$249
How this compares
$37,642 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 24 | $23,937 |
| LumiganBimatoprost | 23 | $13,466 |
| Cyclosporine | 16 | $10,042 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 23 | $284 |
| Latanoprost | 14 | $278 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $2,690 | $37,40347 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Humble
- Paul MannHumble$75K
- Michael SingerSan Antonio$1.8M
- Oluwatosin SmithDallas$1.5M
- Charles WykoffBellaire$1.5M
- John MichelettiHouston$916K
- Davinder GroverDallas$705K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
- Ashkan AbbeyDallas$559K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.